Drug Trial Radar · NCT07035405
Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)
Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
7,500
Planned (sponsor's estimate)
Start
Jul 4, 2025
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shenzhen Medical Academy of Research and Translation
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.
Conditions
- Stroke
Interventions
Colchicine 0.5 mgDrug
Oral colchicine will be initiated with a dose of 0.5 mg per day.
Placebo colchicineDrug
Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- First Event of ischemic stroke, myocardial infarction and vascular deathTime frame: From randomization to occurrence of the first event, with a median follow-up time of 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.